Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FVF3565s Intravitreal Ranibizumab (rhuFab V2) in the Treatment of Macular Edema Associated With Perfused Central (CRVO) Retinal Venous Occlusive Disease

NCT00406796 is registered in ClinicalTrials.gov with California Retina Consultants as lead sponsor.

NCT NCT00406796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00406796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FVF3565s Intravitreal Ranibizumab (rhuFab V2) in the Treatment of Macular Edema Associated With Perfused Central (CRVO) Retinal Venous Occlusive Disease
Lead sponsor
California Retina Consultants
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2006
Completion date
October 31, 2010
Enrollment
20 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

central retinal vein occlusion